FIGURE 4.

(a) Distribution of Expanded Disability Status Scale (EDSS) at baseline, at Month 36 following treatment start, and at last follow‐up available in the autologous haematopoietic stem cell transplantation (AHSCT; right panel) and cyclophosphamide (Cy; left panel) groups. EDSS deterioration was observed at Month 36 compared to baseline in the AHSCT group (p = 0.017) and at last follow‐up compared to baseline in both groups (p < 0.001 and <0.0001 for the AHSCT and Cy groups, respectively). (b) Proportion of patients with a definite EDSS at baseline and last follow‐up in the two groups. No differences in distribution were observed; at last follow‐up, the proportion of the patients with EDSS ≥ 8 was 6% in the AHSCT group and 18% in the Cy group, p = 0.127. (c) No evidence of disease activity 2 (NEDA‐2) survival (i.e., survival free from both relapses and EDSS worsening) did not differ between groups, being at Year 5 following treatment start 45% in the AHSCT and 36% in the Cy group (p = 0.379). (d) Cox estimated distribution of NEDA‐2 survival in the AHSCT and Cy groups, adjusted for age at treatment, progressive phase duration, and number of previous disease‐modifying treatments received. No differences were observed between the groups, p = 0.311 [Colour figure can be viewed at wileyonlinelibrary.com]